logo BDSP

Base documentaire

  1. A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation.

    Article - En anglais

    The duration of the antiemetic effect of granisetron was examined in a pilot study of patients (n=26) undergoing a standard emetogenic stimulus in the form of total body irradiation fractionated over 3-4 days, in a randomized comparison with twice-daily ondansetron.

    A single intravenous dose of granisetron at the onset of therapy was effective over the entire follow-up period in 50% (6/12) of patients, compared with 77% (10/13) prescribed twice-daily oral ondansetron for 3 or 4 days.

    The response rate within the first 24 hours from the start of irradiation was 67% (8/12) for granisetron and 77% (10/13) for ondansetron.

    Granisetron and ondansetron were therefore of similar efficacy within the first 24-hour period, but granisetron was less efficaceous more than 24 hours after the onset of therapy.

    Patients who required a second dose of granisetron did so at intervals of 12,42,47 and 48 hours following the first fraction of radiotherapy.

    The cost per patient in this study was £48 for granisetron and £54 for ondansetron, but the dose scheduling we used cannot be recommended in view of the lower effectiveness of granisetron.

    Mots-clés Pascal : Lymphome non hodgkinien, Leucémie, Radiothérapie, Traitement, Corps entier, Dose fractionnée, Vomissement, Complication, Prévention, Granisétron, Antiémétique, Antagoniste sérotonine, Ondansétrone, Récepteur sérotoninergique 5-HT3, Analyse coût efficacité, Economie santé, Etude comparative, Homme, Hémopathie maligne, Lymphoprolifératif syndrome, Appareil digestif pathologie

    Mots-clés Pascal anglais : Non Hodgkin lymphoma, Leukemia, Radiotherapy, Treatment, Whole body, Fractionated dose, Vomiting, Complication, Prevention, Antiemetic, Serotonin antagonist, 5-HT3 receptor, Cost efficiency analysis, Health economy, Comparative study, Human, Malignant hemopathy, Lymphoproliferative syndrome, Digestive diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0335790

    Code Inist : 002B02H. Création : 10/04/1997.